Search

Displaying results 3881 - 3890 of 5302 in total
  1. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    [A193521] [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women. … [A193518] Adapalene can also be combined with benzoyl peroxide (BPO), which possesses bactericidal properties[A193524], and either adapalene alone, or adapalene BPO combination products, are commonly used

  2. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic

  3. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  4. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders.

  5. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

  6. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thu...

  7. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  8. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis.

    Products: VISIONFREE® X 5 ML
  9. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389] … [L32789] _Ginkgo biloba_ is an herbal plant that is now cultivated worldwide. It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries.

  10. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity … [L15292] Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,[A191829] tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020,